Ex vivo expansion of mafosfamide-purged PBPC products

References

• Sharkis SJ, Santos GW, Colvin M. Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide. Blood 1980; 55: 521–3
   PubMed Web of Science ®Google Scholar
• Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4- hydroperoxycyclophosphamide. N Engl J Med 1986; 315: 141–7
   PubMed Web of Science ®Google Scholar
• Miller C, Rowlings P, Zhang M, et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol 2001; 29: 1336–46
   Google Scholar
• Gorin NC, Labopin M, Meloni G, et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 1991; 5: 896–904
   PubMed Web of Science ®Google Scholar
• Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606–14
   PubMed Web of Science ®Google Scholar
• Laporte JP, Douay L, Lopez M, et al. One-hundred and twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood 1994; 84: 3810–18
   PubMed Web of Science ®Google Scholar
• Smith BD, Jones RJ, Lee SM, et al. Autologous bone marrow transplantation with 4-hydroperoxycycophosphamide purging for acute myeloid leukaemia beyond first remission: a ten year experience. Br J Haematol 2002; 117: 907–13
   Google Scholar
• Miller CB, Zehnbauer BA, Piantadosi S, et al. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991; 78: 1125–31
   PubMed Web of Science ®Google Scholar
• Euler HH, Marmont AM, Bacigalupo A, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996; 88: 3621–5
   PubMed Web of Science ®Google Scholar
• Jones RJ. Purging with 4-hydroperoxycyclophosphamide. J Hematother 1992; 1: 343–8
   PubMedGoogle Scholar
• Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984; 44: 5156–60
   PubMed Web of Science ®Google Scholar
• Sahovic EA, Colvin M, Hilton J, Ogawa M. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Res 1988; 48: 1223–6
   PubMed Web of Science ®Google Scholar
• Jones RJ, Barber JP, Vala M, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85: 2742–6
   PubMed Web of Science ®Google Scholar
• Jones RJ, Collector MI, Barber JP, et al. Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood 1996; 88: 487–91
   PubMed Web of Science ®Google Scholar
• Reiffers J, Cailliot C, Dazey B, et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet 1999; 354: 1092–3
   PubMedGoogle Scholar
• McNiece I, Jones R, Bearman S, et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery in breast cancer patients following high dose chemotherapy. Blood 2000; 96: 3001–7
   PubMed Web of Science ®Google Scholar
• Paquette R, Dergham S, Karpf E, et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood 2001; 96: 2385–90
   Google Scholar
• Prince M, Haylock DN, Simmons PJ, et al. Transplantation with ex vivo expanded mobilized blood CD34+ cells results in reduction in depth and duration of neutropenia and thrombocytopenia, with a major impact on febrile neutropenia, platelet transfusion and hospital admissions. Blood 2003; 102: 237a
   Google Scholar
• Gorin NC, Labopin M, Laporte JP, et al. Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution. Exp Hematol 1999; 27: 1822–30
   PubMed Web of Science ®Google Scholar
• Jones RJ, Zuehlsdorf M, Rowley SD, et al. Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation. Blood 1987; 70: 1490–4
   PubMed Web of Science ®Google Scholar
• McNiece IK, Almeida-Porada G, Shpall EJ, Zanjani E. Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long term engrafting potential. Exp Hemat 2002; 30: 612–6
   PubMed Web of Science ®Google Scholar
• Peter SO, Kittler EL, Ramshaw HS, Quesenberry PJ. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 1996; 87: 30–7
   Google Scholar